Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1987 Jun;61(6):1867–1874. doi: 10.1128/jvi.61.6.1867-1874.1987

Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response.

D Moskophidis, S P Cobbold, H Waldmann, F Lehmann-Grube
PMCID: PMC254192  PMID: 3494855

Abstract

After intravenous infection of mice, lymphocytic choriomeningitis virus multiplied in spleens and livers, attaining highest concentrations on days 4 to 6. The subsequent clearance was as rapid, and 8 to 10 days after inoculation, infectivity was usually below detectability. During the effector phase of virus elimination, both cytotoxic T-cell (CTL) activity and the number of cells producing antiviral antibodies were high. Monoclonal antibodies directed against T lymphocytes and T-lymphocyte subsets were inoculated once intravenously 5, 6, or 7 days after infection of the animals, and the effects on antiviral immune responses, as well as on elimination of virus from the organs, were determined. Treatment with anti-Thy-1 and anti-Lyt-2 antibodies blocked elimination of the virus and profoundly diminished the activity of spleen CTLs but reduced the antibody response partially (anti-Thy-1) or increased it (anti-Lyt-2). In contrast, treatment with the anti-L3T4 antibody had essentially no effect on either virus elimination or CTL response but abolished antibody production. We conclude that Lyt-2+ (cytotoxic-suppressive) T lymphocytes are needed for elimination of the virus and also regulate the humoral response but that antiviral antibodies are not essential for control of the infection.

Full text

PDF
1867

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed R., Salmi A., Butler L. D., Chiller J. M., Oldstone M. B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med. 1984 Aug 1;160(2):521–540. doi: 10.1084/jem.160.2.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Assmann-Wischer U., Simon M. M., Lehmann-Grube F. Mechanism of recovery from acute virus infection. III. Subclass of T lymphocytes mediating clearance of lymphocytic choriomeningitis virus from the spleens of mice. Med Microbiol Immunol. 1985;174(5):249–256. doi: 10.1007/BF02124809. [DOI] [PubMed] [Google Scholar]
  3. Benjamin R. J., Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature. 1986 Apr 3;320(6061):449–451. doi: 10.1038/320449a0. [DOI] [PubMed] [Google Scholar]
  4. Brunner K. T., Mauel J., Cerottini J. C., Chapuis B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 1968 Feb;14(2):181–196. [PMC free article] [PubMed] [Google Scholar]
  5. Bukowski J. F., Warner J. F., Dennert G., Welsh R. M. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med. 1985 Jan 1;161(1):40–52. doi: 10.1084/jem.161.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Byrne J. A., Oldstone M. B. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol. 1984 Sep;51(3):682–686. doi: 10.1128/jvi.51.3.682-686.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cantor H., Boyse E. A. Lymphocytes as models for the study of mammalian cellular differentiation. Immunol Rev. 1977 Jan;33:105–124. doi: 10.1111/j.1600-065x.1977.tb00364.x. [DOI] [PubMed] [Google Scholar]
  8. Chmielarczyk W., Engler H., Ernst R., Opitz U., Kirchner H. Injection of anti-thy-1.2 serum breaks genetic resistance of mice against herpes simplex virus. J Gen Virol. 1985 May;66(Pt 5):1087–1094. doi: 10.1099/0022-1317-66-5-1087. [DOI] [PubMed] [Google Scholar]
  9. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  10. Cobbold S. P., Martin G., Qin S., Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986 Sep 11;323(6084):164–166. doi: 10.1038/323164a0. [DOI] [PubMed] [Google Scholar]
  11. Cobbold S., Waldmann H. Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. Transplantation. 1986 May;41(5):634–639. doi: 10.1097/00007890-198605000-00016. [DOI] [PubMed] [Google Scholar]
  12. Cosimi A. B., Colvin R. B., Burton R. C., Rubin R. H., Goldstein G., Kung P. C., Hansen W. P., Delmonico F. L., Russell P. S. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med. 1981 Aug 6;305(6):308–314. doi: 10.1056/NEJM198108063050603. [DOI] [PubMed] [Google Scholar]
  13. Coulie P. G., Coutelier J. P., Uyttenhove C., Lambotte P., Van Snick J. In vivo suppression of T-dependent antibody responses by treatment with a monoclonal anti-L3T4 antibody. Eur J Immunol. 1985 Jun;15(6):638–640. doi: 10.1002/eji.1830150620. [DOI] [PubMed] [Google Scholar]
  14. Denkers E. Y., Badger C. C., Ledbetter J. A., Bernstein I. D. Influence of antibody isotype on passive serotherapy of lymphoma. J Immunol. 1985 Sep;135(3):2183–2186. [PubMed] [Google Scholar]
  15. Granstein R. D., Goulston C., Gaulton G. N. Prolongation of murine skin allograft survival by immunologic manipulation with anti-interleukin 2 receptor antibody. J Immunol. 1986 Feb 1;136(3):898–902. [PubMed] [Google Scholar]
  16. Grau G. E., Piguet P. F., Engers H. D., Louis J. A., Vassalli P., Lambert P. H. L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria. J Immunol. 1986 Oct 1;137(7):2348–2354. [PubMed] [Google Scholar]
  17. Gutstein N. L., Seaman W. E., Scott J. H., Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol. 1986 Aug 15;137(4):1127–1132. [PubMed] [Google Scholar]
  18. Gutstein N. L., Wofsy D. Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ cells. J Immunol. 1986 Dec 1;137(11):3414–3419. [PubMed] [Google Scholar]
  19. Hollander N. Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies. J Immunol. 1984 Nov;133(5):2801–2805. [PubMed] [Google Scholar]
  20. Holmdahl R., Olsson T., Moran T., Klareskog L. In vivo treatment of rats with monoclonal anti-T-cell antibodies. Immunohistochemical and functional analysis in normal rats and in experimental allergic neuritis. Scand J Immunol. 1985 Aug;22(2):157–169. doi: 10.1111/j.1365-3083.1985.tb01868.x. [DOI] [PubMed] [Google Scholar]
  21. Jefferies W. A., Green J. R., Williams A. F. Authentic T helper CD4 (W3/25) antigen on rat peritoneal macrophages. J Exp Med. 1985 Jul 1;162(1):117–127. doi: 10.1084/jem.162.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kaminski M. S., Kitamura K., Maloney D. G., Campbell M. J., Levy R. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol. 1986 Feb 1;136(3):1123–1130. [PubMed] [Google Scholar]
  23. Kirkman R. L., Barrett L. V., Gaulton G. N., Kelley V. E., Ythier A., Strom T. B. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med. 1985 Jul 1;162(1):358–362. doi: 10.1084/jem.162.1.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kruisbeek A. M., Titus J. A., Stephany D. A., Gause B. L., Longo D. L. In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens. J Immunol. 1985 Jun;134(6):3605–3614. [PubMed] [Google Scholar]
  25. Kurlander R. J., Ellison D. M., Hall J. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J Immunol. 1984 Aug;133(2):855–862. [PubMed] [Google Scholar]
  26. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  27. Larsson P., Holmdahl R., Dencker L., Klareskog L. In vivo treatment with W3/13 (anti-pan T) but not with OX8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. Immunology. 1985 Nov;56(3):383–391. [PMC free article] [PubMed] [Google Scholar]
  28. Lehmann-Grube F., Assmann U., Löliger C., Moskophidis D., Löhler J. Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol. 1985 Jan;134(1):608–615. [PubMed] [Google Scholar]
  29. Levy R., Miller R. A. Tumor therapy with monoclonal antibodies. Fed Proc. 1983 Jun;42(9):2650–2656. [PubMed] [Google Scholar]
  30. Like A. A., Biron C. A., Weringer E. J., Byman K., Sroczynski E., Guberski D. L. Prevention of diabetes in BioBreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med. 1986 Oct 1;164(4):1145–1159. doi: 10.1084/jem.164.4.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. MacDonald T. T., Calkins C. E., Rothermel A. L. Modulation in vivo of Lyt 2 antigen expression on T cells by anti-Lyt 2 antibody: effects on Con A-induced unresponsiveness. Immunology. 1986 Oct;59(2):181–186. [PMC free article] [PubMed] [Google Scholar]
  32. Marker O., Volkert M. Studies on cell-mediated immunity to lymphocytic choriomeningitis virus in mice. J Exp Med. 1973 Jun 1;137(6):1511–1525. doi: 10.1084/jem.137.6.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Meeker T. C., Lowder J., Maloney D. G., Miller R. A., Thielemans K., Warnke R., Levy R. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985 Jun;65(6):1349–1363. [PubMed] [Google Scholar]
  34. Miller R. A., Levy R. Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet. 1981 Aug 1;2(8240):226–230. doi: 10.1016/s0140-6736(81)90475-x. [DOI] [PubMed] [Google Scholar]
  35. Miller R. A., Maloney D. G., McKillop J., Levy R. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood. 1981 Jul;58(1):78–86. [PubMed] [Google Scholar]
  36. Miller S. D., Jenkins M. K. In vivo effects of GK1.5 (anti-L3T4a) monoclonal antibody on induction and expression of delayed-type hypersensitivity. Cell Immunol. 1985 May;92(2):414–426. doi: 10.1016/0008-8749(85)90022-x. [DOI] [PubMed] [Google Scholar]
  37. Moskophidis D., Lehmann-Grube F. The immune response of the mouse to lymphocytic choriomeningitis virus. III. Differences of numbers of cytotoxic T lymphocytes in spleens of mice of different strains. Cell Immunol. 1983 Apr 15;77(2):279–289. doi: 10.1016/0008-8749(83)90028-x. [DOI] [PubMed] [Google Scholar]
  38. Moskophidis D., Lehmann-Grube F. The immune response of the mouse to lymphocytic choriomeningitis virus. IV. Enumeration of antibody-producing cells in spleens during acute and persistent infection. J Immunol. 1984 Dec;133(6):3366–3370. [PubMed] [Google Scholar]
  39. Nadler L. M., Stashenko P., Hardy R., Kaplan W. D., Button L. N., Kufe D. W., Antman K. H., Schlossman S. F. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980 Sep;40(9):3147–3154. [PubMed] [Google Scholar]
  40. Oldstone M. B., Blount P., Southern P. J., Lampert P. W. Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature. 1986 May 15;321(6067):239–243. doi: 10.1038/321239a0. [DOI] [PubMed] [Google Scholar]
  41. Opitz H. G., Opitz U., Hewlett G., Schlumberger H. D. A new model for investigations of T-cell functions in mice: differential immunosuppressive effects of two monoclonal anti-Thy-1.2 antibodies. Immunobiology. 1982 Feb;160(5):438–453. doi: 10.1016/S0171-2985(82)80007-7. [DOI] [PubMed] [Google Scholar]
  42. Ranges G. E., Sriram S., Cooper S. M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985 Sep 1;162(3):1105–1110. doi: 10.1084/jem.162.3.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ritz J., Pesando J. M., Sallan S. E., Clavell L. A., Notis-McConarty J., Rosenthal P., Schlossman S. F. Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul;58(1):141–152. [PubMed] [Google Scholar]
  44. Rosenbaum J. T., Adelman N. E., McDevitt H. O. In vivo effects of antibodies to immune response gene products. I. Haplotype-specific suppression of humoral immune responses with a monoclonal anti-I-A. J Exp Med. 1981 Nov 1;154(5):1694–1702. doi: 10.1084/jem.154.5.1694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Seaman W. E., Wofsy D., Greenspan J. S., Ledbetter J. A. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J Immunol. 1983 Apr;130(4):1713–1718. [PubMed] [Google Scholar]
  46. Sharma S. D., Budzich T., Proffitt M. R., Shepherd D., Remington J. S. Regulation of natural killer cell activity by anti-I-region monoclonal antibodies. Cell Immunol. 1984 Apr 15;85(1):125–134. doi: 10.1016/0008-8749(84)90284-3. [DOI] [PubMed] [Google Scholar]
  47. Steinman L., Rosenbaum J. T., Sriram S., McDevitt H. O. In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7111–7114. doi: 10.1073/pnas.78.11.7111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Swain S. L., Dialynas D. P., Fitch F. W., English M. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol. 1984 Mar;132(3):1118–1123. [PubMed] [Google Scholar]
  49. Swain S. L. Significance of Lyt phenotypes: Lyt2 antibodies block activities of T cells that recognize class 1 major histocompatibility complex antigens regardless of their function. Proc Natl Acad Sci U S A. 1981 Nov;78(11):7101–7105. doi: 10.1073/pnas.78.11.7101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Titus R. G., Ceredig R., Cerottini J. C., Louis J. A. Therapeutic effect of anti-L3T4 monoclonal antibody GK1.5 on cutaneous leishmaniasis in genetically-susceptible BALB/c mice. J Immunol. 1985 Sep;135(3):2108–2114. [PubMed] [Google Scholar]
  51. Volkert M., Marker O., Bro-Jorgensen K. Twp populations of T lymphocytes immune to the lymphocytic choriomeningitis virus. J Exp Med. 1974 May 1;139(5):1329–1343. doi: 10.1084/jem.139.5.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Waldor M. K., Sriram S., Hardy R., Herzenberg L. A., Herzenberg L. A., Lanier L., Lim M., Steinman L. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985 Jan 25;227(4685):415–417. doi: 10.1126/science.3155574. [DOI] [PubMed] [Google Scholar]
  53. Wassmer P., Chan C., Lögdberg L., Shevach E. M. Role of the L3T4-antigen in T cell activation. II. Inhibition of T cell activation by monoclonal anti-L3T4 antibodies in the absence of accessory cells. J Immunol. 1985 Oct;135(4):2237–2242. [PubMed] [Google Scholar]
  54. Weinstein J. N., Parker R. J., Keenan A. M., Dower S. K., Morse H. C., 3rd, Sieber S. M. Monoclonal anitbodies in the lymphatics: toward the diagnosis and therapy of tumor metastases. Science. 1982 Dec 24;218(4579):1334–1337. doi: 10.1126/science.7146917. [DOI] [PubMed] [Google Scholar]
  55. Wofsy D. Administration of monoclonal anti-T cell antibodies retards murine lupus in BXSB mice. J Immunol. 1986 Jun 15;136(12):4554–4560. [PubMed] [Google Scholar]
  56. Wofsy D., Mayes D. C., Woodcock J., Seaman W. E. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol. 1985 Sep;135(3):1698–1701. [PubMed] [Google Scholar]
  57. Wofsy D., Seaman W. E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985 Feb 1;161(2):378–391. doi: 10.1084/jem.161.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wood G. S., Warner N. L., Warnke R. A. Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. J Immunol. 1983 Jul;131(1):212–216. [PubMed] [Google Scholar]
  59. Zinkernagel R. M., Welsh R. M. H-2 compatibility requirement for virus-specific T cell-mediated effector functions in vivo. I. Specificity of T cells conferring antiviral protection against lymphocytic choriomeningitis virus is associated with H-2K and H-2D. J Immunol. 1976 Nov;117(5 Pt 1):1495–1502. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES